<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00354887</url>
  </required_header>
  <id_info>
    <org_study_id>2003-0827</org_study_id>
    <nct_id>NCT00354887</nct_id>
  </id_info>
  <brief_title>Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater</brief_title>
  <official_title>A Phase II Study of Capecitabine and Oxaliplatin (XELOX) in Adenocarcinoma of the Small Bowel and Ampulla of Vater</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi-Synthelabo</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      1. To determine the objective response rate (complete plus partial) to the combination of
      capecitabine (Xeloda) and oxaliplatin (Eloxatin) (XELOX) in patients with adenocarcinoma of
      the small bowel and ampulla of Vater.

      Secondary objectives include determining the toxicity, time-to-treatment failure, and overall
      survival rates in patients treated with this combination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oxaliplatin is a chemotherapy drug designed to destroy cancer cells by interfering with DNA
      function, which is necessary for growth of new cells.

      Capecitabine is a chemotherapy drug designed to destroy cancer cells by interfering with cell
      division, which is important to the growth of cancer.

      You will receive 14 days of treatment followed by 7 days without treatment, 21 days in all,
      otherwise known as a &quot;cycle&quot; of therapy. On Day 1 of each cycle, you will receive oxaliplatin
      injected into a vein over a period of 2 hours. For this injection, you will need to have a
      small tube inserted into a vein under the skin of the chest (central venous line) to receive
      oxaliplatin. Oxaliplatin must be given at M.D. Anderson.

      You will take capecitabine tablets twice a day for the first two weeks (Days 1-14) of each
      3-week cycle. No treatment will be given for the next 7 days. You must take capecitabine
      within 30 minutes after breakfast and dinner, with morning and evening doses about 12 hours
      apart. You should take capecitabine by mouth with water, and not fruit juices. At the first
      treatment visit and every 3 weeks, you will receive enough capecitabine to last until the
      next visit. At each visit, you must return any capecitabine you have not used as well as all
      empty bottles.

      During Cycle 1, routine blood tests (about 2 teaspoons of blood) will be done once a week.
      Before each new cycle of therapy, you will have a complete physical exam and blood (about 2 Â½
      teaspoons) will be collected for routine tests. You will be asked by the study doctor about
      all medications you have taken since starting the study drugs and any health problems that
      you may have experienced. Also, you will have an x-ray or computed tomography (CT) scan of
      the chest and either CT scans or magnetic resonance imaging (MRIs) of the tumor(s) every 3
      cycles and at the end of the study. Additional tests may be done during the study if your
      doctor feels it is necessary for your care.

      This study will require you to receive at least 3 cycles of treatment. However, if you
      experience severe side effects or your disease becomes worse, treatment may be delayed,
      stopped, or you may receive smaller doses of the treatment. You may continue to receive
      treatment on this study until the disease gets worse or you experience any intolerable side
      effects. If this happens, you will be taken off the study and your doctor will discuss other
      treatment options with you.

      When you stop taking part in the study, you will have blood (about 3 teaspoons) collected for
      routine tests. You will have a physical exam and either a CT scan or an MRI to check on the
      status of the disease. You will be contacted by phone every three months for the rest of your
      life to check on your state of health and ask you about further symptoms you may be
      experiencing.

      This is an investigational study. The drugs oxaliplatin and capecitabine are FDA approved for
      treatment of advanced cancer of the colon or rectum. The drugs are not approved for small
      bowel or ampulla of Vater cancer. Their use together in this study is investigational. Up to
      30 people will take part in this study. All will be enrolled at M.D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Overall Response</measure>
    <time_frame>Every 9 weeks from treatment initiation and confirmatory images 6 weeks or more after initial responses</time_frame>
    <description>Overall response rate defined as Complete Response (CR), disappearance of all target lesions; or Partial Response (PR), at least a 30% decrease in sum of longest diameter (LD) of target lesions, taking as reference the baseline sum LD, assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Committee [JNCI 92(3):205-216, 2000]. In addition to a baseline scan, confirmatory scans for those deemed to have achieved a PR or CR.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Gastrointestinal Cancer</condition>
  <arm_group>
    <arm_group_label>Oxaliplatin + Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous Oxaliplatin 130 mg/m^2, Day 1 + Oral Capecitabine 750 mg/m^2 twice daily Days 1-14.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Oral capecitabine 750 mg/m^2 twice daily (total daily dose 1500 mg/m^2) on Days 1-14 in 21 Day Cycle.</description>
    <arm_group_label>Oxaliplatin + Capecitabine</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>130 mg/m^2 by vein Day 1 over 2 hours in 21 Day Cycle</description>
    <arm_group_label>Oxaliplatin + Capecitabine</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must have histologically or cytologically confirmed adenocarcinoma of the
             small bowel or ampulla of Vater that is either unresectable or metastatic.

          2. Patients must have measurable disease as per the modified Response Evaluation Criteria
             In Solid Tumors (RECIST) criteria.

          3. Patients may be previously untreated or have received previous systemic therapy,
             limited to 5-FU/leucovorin or capecitabine, as adjuvant or neoadjuvant therapy or as a
             radiosensitizer. Patients may have received capecitabine or 5-FU administered as a
             radiosensitizing agent concurrently with external beam radiotherapy as preoperative or
             postoperative therapy. Patients may have received capecitabine or 5-FU/leucovorin as
             part of adjuvant chemotherapy.

          4. If radiation was previously received, the measurable disease must be outside the
             previous radiation field.

          5. A minimum of 4 weeks must have elapsed since completion of any prior chemotherapy or
             radiotherapy. A minimum of 4 weeks must have elapsed since any prior surgery.

          6. Eastern Cooperative Oncology Group (ECOG) Performance Status of less than or equal to
             2.

          7. Adequate bone marrow function defined as absolute peripheral granulocyte count of
             greater than or equal to 1500 mm3, platelet count greater than or equal to 1500 mm3,
             and hemoglobin greater than or equal to 10 gm/dL.

          8. Adequate renal function, defined as serum creatinine less than or equal to 1.5 * ULN
             and calculated creatinine clearance &gt;30 mL/min.

          9. Patients must have adequate hepatic function: total bilirubin less than or equal to
             1.5 gm/dL; serum albumin greater than or equal to 2.5 gm/dL. If the patient does not
             have liver metastasis, transaminases may be up to 2 * the ULN. If the patient has
             liver metastasis, transaminases up to 5 * Upper Limit of Normal (ULN) are allowed.

         10. Negative urine or serum pregnancy test in women with childbearing potential, within
             one week prior to initiation of treatment.

         11. The effects of the combination of oxaliplatin and capecitabine on the developing fetus
             are unknown. For this reason, women of childbearing potential and men must agree to
             use adequate contraception (hormonal or barrier method of birth control) prior to
             study entry and for the duration of study participation. Should a woman become
             pregnant while participating in this study, she should inform her treating physician
             immediately.

         12. Patients must sign an Informed Consent and Authorization indicating that they are
             aware of the investigational nature of this study and the known risks involved.

         13. Age greater than or equal to 18 years. Because no dosing or adverse event data are
             currently available on the use of XELOX in patients &lt;18 years of age, children are
             excluded from this study.

         14. Patients taking therapeutic doses of coumarin-derivative anticoagulants should be
             switched to low-molecular-weight heparin (LMWH). Low-dose Coumadin (e.g. 1 mg by mouth
             (PO) per day) in patients with in-dwelling venous access devices is allowed.

        Exclusion Criteria:

          1. Patients with prior exposure to platinum therapy are excluded. Patients who have
             received prior chemotherapy for metastatic disease are excluded.

          2. Patients who have had chemotherapy within 4 weeks (6 weeks for nitrosoureas or
             Mitomycin C) prior to entering the study or those who have not recovered from adverse
             events due to agents administered more than 4 weeks earlier.

          3. Patients may not be receiving any other investigational agents nor have received any
             investigational drug 30 days prior to enrollment.

          4. Patients with known brain metastases are excluded from this clinical trial because of
             their poor prognosis and their risk for progressive neurologic dysfunction that would
             confound the evaluation of neurologic and other adverse events.

          5. Gastrointestinal tract disease resulting in an inability to take oral medication or a
             requirement for IV alimentation. Prior surgical therapy affecting absorption.

          6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          7. Because patients with immune deficiency are at increased risk of lethal infections
             when treated with marrow-suppressive therapy, HIV-positive patients receiving
             combination anti-retroviral therapy are excluded from the study because of possible
             pharmacokinetic interactions with XELOX. Appropriate studies will be undertaken in
             patients receiving combination anti-retroviral therapy when indicated.

          8. Patients with extensive symptomatic fibrosis of the lungs.

          9. Peripheral neuropathy &gt; grade 1.

         10. Known Dihydropyrimidine dehydrogenase deficiency (DPD deficiency)

         11. Patients receiving therapeutic doses of coumarin-derivative anticoagulant therapy are
             excluded since a drug interaction between capecitabine and coumarin anticoagulants has
             been reported. Patients requiring anticoagulation who may be safely switched to LMWH
             are eligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert A. Wolff, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.T. M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <results_reference>
    <citation>Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL, Wolff RA. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol. 2009 Jun 1;27(16):2598-603. doi: 10.1200/JCO.2008.19.7145. Epub 2009 Jan 21.</citation>
    <PMID>19164203</PMID>
  </results_reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2006</study_first_submitted>
  <study_first_submitted_qc>July 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2006</study_first_posted>
  <results_first_submitted>June 14, 2011</results_first_submitted>
  <results_first_submitted_qc>June 14, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 14, 2011</results_first_posted>
  <last_update_submitted>October 22, 2012</last_update_submitted>
  <last_update_submitted_qc>October 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastrointestinal Cancer</keyword>
  <keyword>Small Bowel Cancer</keyword>
  <keyword>Ampulla of Vater</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Xeloda</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Eloxatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: November 1, 2004 and July 31, 2007. All participants recruited at UT MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Thirty-one patients were enrolled onto the study, and 30 patients received study treatment. One patient did not meet eligibility criteria and did not receive any study treatment. One additional patient was removed from the study after one treatment cycle.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oxaliplatin + Capecitabine</title>
          <description>Intravenous Oxaliplatin 130 mg/m^2, Day 1 + Oral Capecitabine 750 mg/m^2 twice daily Days 1-14.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oxaliplatin + Capecitabine</title>
          <description>Intravenous Oxaliplatin 130 mg/m^2, Day 1 + Oral Capecitabine 750 mg/m^2 twice daily Days 1-14.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="41" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Overall Response</title>
        <description>Overall response rate defined as Complete Response (CR), disappearance of all target lesions; or Partial Response (PR), at least a 30% decrease in sum of longest diameter (LD) of target lesions, taking as reference the baseline sum LD, assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Committee [JNCI 92(3):205-216, 2000]. In addition to a baseline scan, confirmatory scans for those deemed to have achieved a PR or CR.</description>
        <time_frame>Every 9 weeks from treatment initiation and confirmatory images 6 weeks or more after initial responses</time_frame>
        <population>Analysis was intent-to-treat; One patient developed an acute flare of Crohnâs disease after one cycle of study treatment and was removed from study without undergoing restaging scans.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxaliplatin + Capecitabine</title>
            <description>Intravenous Oxaliplatin 130 mg/m^2, Day 1 + Oral Capecitabine 750 mg/m^2 twice daily Days 1-14.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Overall Response</title>
          <description>Overall response rate defined as Complete Response (CR), disappearance of all target lesions; or Partial Response (PR), at least a 30% decrease in sum of longest diameter (LD) of target lesions, taking as reference the baseline sum LD, assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Committee [JNCI 92(3):205-216, 2000]. In addition to a baseline scan, confirmatory scans for those deemed to have achieved a PR or CR.</description>
          <population>Analysis was intent-to-treat; One patient developed an acute flare of Crohnâs disease after one cycle of study treatment and was removed from study without undergoing restaging scans.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from November 18, 2004 to July 26, 2007 or a total of three (3) years and five (5) months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oxaliplatin + Capecitabine</title>
          <description>Intravenous Oxaliplatin 130 mg/m^2, Day 1 + Oral Capecitabine 750 mg/m^2 twice daily Days 1-14.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Neutophils/granulocytes(ANC/AGC)</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Eyes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Watery Eyes</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Abdominal bloating</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Belching</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hemorrhage (abdominal wound)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title vocab="CTCAE V3.0">Nausea</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cold Intolerance</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Fever without neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Mood alteration(depression)</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Mucositis (Oral Cavity)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Neuropathy-Sensory</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pain (Muscle)</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pain(throat/larynx)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Rigors (Chills)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Taste Alteration</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alkaline Phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Decreased Total Protein, Serum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Elevated phosphorus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypoatremia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Platelets decreased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Serum Glutamic Oxaloacetic Transaminase (AST,SGOT)</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Serum Glutamic Pyruvic Transaminase (ALT,SGPT)</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total elevated protein</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain(joint)</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Irregular Menses</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hiccoughs</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hand-foot syndrome</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Rash desquamation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Rash(hand/foot skin reaction)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Edema (limb)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Wolff, MD / Professor</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>713-792-2828</phone>
      <email>mjlim@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

